Research Article
Renal Dysfunction after Living-Donor Liver Transplantation: Experience with 500 Cases
Table 1
Demographic data of the study cases.
| | Variable | All cases (n = 500) |
| | Age, years | 51 (10-64) | | Gender | | | Male | 446 (89.2%) | | Female | 54 (10.8%) | | Body mass index (kg/m2) | 28.6 (16.7-42.5) | | Child-Pugh score | 9 (5-15) | | MELD score | 15 (6-48) | | Virology | | | HCV | 453 (90.6%) | | HBV | 8 (1.6%) | | Blood group | | | A –ve | 12 (2.4%) | | A +ve | 166 (33.2%) | | AB –ve | 3 (0.6%) | | AB +ve | 36 (7.2%) | | B –ve | 6 (1.2%) | | B +ve | 116 (23.2%) | | O –ve | 16 (3.2%) | | O +ve | 131 (26.2%) | | Waiting period | 5.5 (1-50) | | Indication | | | HCV | 323 (64.6%) | | HBV | 6 (1.2%) | | HCV + HBV | 2 (0.4%) | | HCC | 146 (29.2%) | | BCS | 6 (1.2%) | | Autoimmune | 11 (2.2%) | | Cryptogenic | 5 (1%) | | Sclerosing cholangitis | 1 (0.2%) |
|
|
MELD, model for end stage liver disease; HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; BCS, Budd Chiari syndrome.
|
